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Abstract
Background Heart failure (HF) is a major problem in the Western world, with increasing prevalence and incidence. Because HF
cannot be cured, prevention of HF is of utter importance. Calcidiol, calcitriol, and parathyroid hormone (PTH) have been identiﬁed
as risk factors for cardiovascular disease. However, their association with new onset HF remains to be established. We investigated
whether calcidiol, calcitriol, and PTH could be used to identify those subjects at risk for new onset HF, and if they had additive pre-
dictive value over established risk predictors like N-terminal-pro Brain-type natriuretic peptide and highly sensitive Troponin-T.
Methods and results We examined 7470 HF-free participants in Prevention of Renal and Vascular End-stage Disease, a
community-based cohort study in Groningen, the Netherlands (latitude 53°N, mean age: 49 years, 48% male). During
follow-up time of 12.6 years (interquartile range: 12.3–12.9), 281 participants (4%) developed HF: 181 (66%) HF with reduced
and 94 (34%) HF with preserved ejection fraction (HFrEF [left ventricular ejection fraction≤ 40%], and HFpEF [left ventricular
ejection fraction ≥ 50%], respectively). Mean (±SD) of calcidiol was 58 (±24) nmol/L, mean calcitriol 145 (±48) pmol/L, and
median (interquartile range) PTH was 3.7 (3.0–4.6) pmol/L. Calcidiol levels were univariately associated with new onset HF
[hazard ratio (HR) 0.82 (95% CI 0.69–0.96)], but calcitriol levels were not [HR 0.85 (95% CI 0.71–1.03)]. PTH levels kept their
predictive value after adjustment for age, sex, and day of blood withdrawal (HR 1.26 [95% CI 1.04–1.53]). However, in our full
model this association was lost [HR 1.10 (95% CI 0.92–1.32)]. Calcidiol, calcitriol, and PTH could not differentiate between new
onset HFrEF or HFpEF.
Conclusions After adjustment for confounding factors, a single measurement of plasma calcidiol, calcitriol, or PTH was not
associated with risk of developing HF. Screening for these markers to identify subjects at risk for new onset HF cannot be
advocated.
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Introduction
Heart failure (HF) is one of the leading causes of morbidity
and mortality in the Western world. Despite optimal treat-
ment, the prognosis of HF remains poor, and approximately
50% of the patients die within 5 years after ﬁrst diagnosis.1
The incidence of HF is strongly associated with age, and be-
cause of the globally ageing population, HF is expected to
become a major burden for society. HF cannot be cured yet,
and many efforts are made to prevent individuals from devel-
oping HF. Relatively simple and important strategies that con-
tribute to prevention of HF are control of hypertension and
prevention of myocardial infarction (MI). However, another
approach that may be useful in preventing new onset HF
could be the identiﬁcation of subjects at risk for HF.
Although several predication models have been
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established,2,3 their predictive value is modest, and it remains
difﬁcult to predict the risk for future HF events in individual
subjects. Therefore, a continuous search for new prediction
models with novel markers is warranted.
The role of vitamin D biology has been well established in
bone homeostasis. In recent decades, however, it has been
suggested that vitamin D may as well be of importance in
the development of cardiovascular (CV) disease, and in partic-
ular HF. Several observational studies reported an association
between vitamin D as well as parathyroid hormone (PTH)
and the development of CV disease and HF.4–6 In addition, it
was already shown that elevated PTH levels were associated
with increased risk of HF in elderly, although calcidiol, the bio-
logically inactive form of vitamin D, was not.7,8 Mechanistically,
vitamin D and PTH exert roles in blood pressure,9 cardiomyo-
cyte hypertrophy,10,11 myocardial ﬁbrosis,12,13 and inﬂamma-
tion.10 However, it remains to be established whether PTH
and vitamin D are either independent predictors in the devel-
opment of all cases of HF, or HF with reduced ejection fraction
(HFrEF) or HF with preserved ejection fraction (HFpEF).
In a large (mostly white) population-based cohort study,
we analyse how calcidiol, calcitriol, and PTH are related to
each other, as well as to other baseline characteristics and
laboratory values. We further investigate whether circulating
calcidiol, calcitriol, and PTH are associated with risk for devel-
opment of new onset HF, and if this association remains after
correction for more established predictors like N-terminal-
pro-Brain-type natriuretic peptide (NT-proBNP) and highly
sensitive Troponin-T (hs-TnT).
Methods
This study was performed using the data of the PREVEND (Pre-
vention of Renal and Vascular End-stage Disease) cohort study
in Groningen, the Netherlands (latitude 53°N), and has been
described in more detail before.14,15 The PREVEND study is a
large prospective population-based cohort study and was de-
signed in 1997 to investigate albuminuria and (development
of) renal and CV diseases. The ﬂowchart for selection and
inclusion of the ﬁnal population is provided in Figure 1.
Sample storage, biomarkers, and measurement of
vitamin D
At baseline (1997–98), EDTA plasma samples were collected
from all participants and stored at 80°C until used for bio-
marker assessment. NT-proBNP, highly sensitive C-reactive
protein, hs-TnT, and urinary albumin concentration were de-
termined as described before.2
Baseline plasma calcidiol and calcitriol levels were mea-
sured by solid phase extraction isotope dilution that was
followed by liquid chromatography–tandem mass spectrome-
try (Spark-Holland Symbiosis system, Emmen, the Nether-
lands). The intra-assay and inter-assay coefﬁcients of
variation (CoV) for calcidiol were 7.2 and 6.7%, respectively,
and for calcitriol 5.0 and 14.1%, respectively. We used an au-
tomated two-site immunoassay (Roche, Diagnostics, India-
napolis, IN, USA) to measure baseline plasma intact PTH
levels, with an intra-assay CoV of 3.4–5.8% and an inter-assay
CoV of <9%.9 Calcidiol levels were expressed in pmol/L (of
note 2.4 pmol/L is equivalent to 1 pg/mL), and calcitriol levels
were expressed in nmol/L (2.5 nmol/L is equivalent to
1 ng/mL).
Ascertainment of new onset heart failure
In this study, follow-up time was deﬁned as the time between
the baseline visit and the date of new onset HF or the date of
the last follow-up (1 January 2010), whatever date came ﬁrst.
Participants of the PREVEND study were known to have a low
migration rate. Nevertheless, participants were censored at
the day they moved to an unknown destination. The diagno-
sis of each individual HF case was made using an extensive
validation and identiﬁcation process. Brouwers et al. pro-
vided a simpliﬁed overview of the validation and identiﬁca-
tion process of this study.15 Brieﬂy, health care of
participants was covered by the two main hospitals in the re-
gion. The local Ethics Committee of both hospitals granted
access to hospital records of PREVEND participants. Patient
ﬁles were checked for the presence of HF at baseline or dur-
ing follow-up for new onset HF. HF was suspected when
signs, symptoms, and objective evidence of HF were
Figure 1 Flowchart of selection and inclusion of ﬁnal study population.
DM, diabetes mellitus; HF, heart failure; PTH, parathyroid hormone;
UAC, urinary albumin concentration.
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reported, according to the criteria of the Heart Failure Guide-
lines of the European Society of Cardiology. All cases of
suspected new onset HF (586 individual cases) were adjudi-
cated by two experts in the ﬁeld of HF. Anonymized clinical
charts, hospitalization, and physician ofﬁce records were
used to ascertain new onset HF. After this review process
patients were considered to have ‘deﬁnite new onset HF’,
‘deﬁnite no new onset HF’, or ‘deﬁnite HF prior to start date
PREVEND’. In case consensus was not reached on an individ-
ual case, the committee made an joint decision. At that time,
European Society of Cardiology guidelines did not provide left
ventricular ejection fraction (LVEF) cut-offs for diagnosis of
HFrEF or HFpEF; therefore, HF was classiﬁed using the follow-
ing cut-offs: HFrEF LVEF≤ 40% and HFpEF LVEF≥ 50%. To
prevent blending of epidemiological proﬁles, patients with a
LVEF between 41 and 49% (n = 6) were excluded from ﬁnal
analysis. Aetiology and date of HF onset were also obtained
from clinical charts. Data on LVEF were available in 98.4%
of cases with new onset HF. In the other six cases, the diag-
nosis of HF was conﬁrmed through the joint decision of an ex-
pert panel (at least two cardiologists) because of insufﬁcient
data on LVEF.
Information on dates and causes of death for every partic-
ipant was obtained from Statistics Netherlands and coded ac-
cording to the 10th revision of the International Classiﬁcation
of Diseases.
Deﬁnitions
Blood pressure was measured during two visits, using an auto-
matic Dinamap XL Model 9300 series device. Hypertension
was deﬁned as a systolic blood pressure> 140mm Hg, a dia-
stolic blood pressure> 90mm Hg, or when an individual re-
ported to use antihypertensive medication. Body mass index
was calculated as the ratio of weight to height squared
(kg/m2), and individuals with a body mass index> 30 kg/m2
were considered obese. Hypercholesterolemia was either
present if lipid-lowering medication was used, or total serum
cholesterol exceeded 6.5mmol/L (251mg/dL) in participants
without history of MI, or 5.0mmol/L (193mg/dL) in partici-
pants with a history of MI. A history of MI was present in
those individuals who reported that they had been hospital-
ized for at least 3 days as a result of this condition. Individuals
were diagnosed to have type 2 diabetes when the use of anti-
diabetic drugs was reported, and/or a fasting plasma glucose
of >126mg/dL was measured, or a non-fasting plasma glu-
cose of >200mg/dL was measured. We calculated urinary
albumin excretion (UAE) as the average of two consecutive
24 h urine collections. The simpliﬁedmodiﬁcation of diet in re-
nal disease formula was used to calculate the estimated glo-
merular ﬁltration rate. Smokers were those individuals who
reported that they had used nicotine within the previous year.
We used the Modular ECG Analysis System16 to record
standard 12-lead electrocardiograms. Presence of atrial
ﬁbrillation (AF) was deﬁned using Minnesota codes 8.3.1
and 8.3.3.
Statistical analysis
Continuous data were represented as means ± standard devi-
ation (SD) for normally distributed data and as medians with
interquartile ranges (IQR) for skewed distributions. Baseline
differences were tested using Student’s t-test or Kruskal–
Wallis test, as appropriate. Discrete and categorical data were
presented as frequencies (%), and differences between
groups were tested using a standard χ2 test. A P-value of
<0.05 was designated as signiﬁcant.
Linear variables were included as linear covariates in our
model. Discrete and non-linear variables were included as
categorical variables. Calcidiol and calcitriol levels were nor-
mally distributed and included as continuous variables. PTH
levels were distributed in a skewed manner and transformed
to a log-scale. Because of the overselection of subjects with
elevated UAE, we corrected for UAE in all models by using a
statistical weighting method. This method enabled us to ex-
trapolate and generalize our conclusions as if we were study-
ing a general population.17
Vitamin D levels are known to signiﬁcantly ﬂuctuate de-
pending on the time of year of blood sampling. We tested
the relationship between PTH, vitamin D, and day of blood
withdrawal in our subjects (one-way ANOVA, post hoc testing
with Bonferroni). In addition, we included two variables
R = cos[2π/365.25]*day and S = sin([2π/365.25]*day,18 to cor-
rect for the time of the year of blood sampling in all subse-
quent analyses unless stated otherwise.18
Cross-sectional univariable regression analyses were per-
formed to study the univariate associations between
calcidiol, calcitriol, PTH, and baseline characteristics. Re-
sults were standardized. To compare relative strength of
the various outcomes, we presented outcomes as beta
coefﬁcients.
Linearity of the relationship between calcidiol, calcitriol,
PTH, and new onset HF was tested and not violated. For the
longitudinal analyses we built Cox proportional hazard re-
gression models to study the associations between plasma vi-
tamin D and PTH with risk of new onset HF. Hazard ratios
(HRs) are reported with respective 95% conﬁdence interval
[95% CI]. Cause-speciﬁc hazard analyses were performed to
study the associations of calcidiol, calcitriol, and PTH with risk
of HFpEF (LVEF ≥ 50%) and HFrEF (LVEF≤ 40%). A P-value for
competing risk (Pcr)< 0.10 between HFrEF and HFpEF was
considered statistically signiﬁcant.19,20 Proportional hazard
assumptions were tested and satisﬁed.
To describe the independent associations of calcidiol,
calcitriol, and PTH with new onset HF, we built several
models adjusting for possible confounders. In the ﬁrst model,
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we examined the univariate association between calcidiol,
calcitriol, and PTH with risk of new onset HF. In model 2,
we adjusted for age, sex, and season of blood withdrawal.
In the third model, we added other covariates that are as-
sociated with new onset HF (smoking, hypertension, hyper-
cholesterolemia, history of MI, obesity, AF, serum cystatin
C, UAE, highly sensitive C-reactive protein, and estimated
glomerular ﬁltration rate15). Finally, we created a fourth
model that additionally adjusted for NT-proBNP and
hs-TnT.2
All analyses were performed using StataIC version 11.0
(StataCorp, Texas, USA).
Results
A total of 7470 participants were evaluated in this study.
Baseline characteristics are presented in Table 1. Mean
(±SD) of calcidiol was 58 (±24) nmol/L, mean calcitriol 145
(±48) pmol/L, and median (IQR) PTH was 3.7 (3.0–4.6)
pmol/L. Mean age of study participants was 49 ± 12 years.
Of all participants, 96% were white, and 52% were fe-
males. Half of the subjects had their blood drawn in the
winter.
Cross-sectional associations of calcidiol, calcitriol,
and PTH with demographics, laboratory values,
and co-morbidities
Univariate associations of changes in calcidiol, calcitriol, and
PTH levels with baseline variables are presented in Table 2.
Levels of calcidiol and calcitriol correlated signiﬁcantly with
season of blood withdrawal (beta coefﬁcient for calcidiol:
0.19, P< 0.001; beta coefﬁcient calcitriol: 0.20, P< 0.001),
but this was less pronounced for PTH (log-transformed coef-
ﬁcient for PTH: 0.08, P< 0.001; Figure 2).
We further observed that the levels of calcidiol and
calcitriol were strongly associated with each other, whilst
the association between PTH and calcidiol was less pro-
nounced. Furthermore, we found no association between
PTH and calcitriol levels. For PTH, the strongest association
per 1 log-transformed increase was with age (Table 2).
We also assessed the associations between levels of vita-
min D metabolites, PTH, and prevalence of several morbid-
ities. Lower levels of calcidiol were associated with
Figure 2 (A) Correlation of plasma calcidiol and season of blood withdrawal. (B) Correlation of plasma calcitriol and season of blood withdrawal. (C)
Correlation of plasma PTH levels and season of blood withdrawal. Data are presented in Tukey boxplot [median (interquartile range)]. * P< 0.05 and
***P< 0.001 as compared with previous season. Data are analysed using one-way ANOVA (post hoc testing with Bonferroni). Outliers are not
presented.
Figure 3 Risk ratio for new onset HF [HR (95% CI)] per 1 SD increment in
plasma calcidiol and calcitriol, or per log-transformed increase of PTH.
Model 1: univariate association. Model 2: age, sex, and time of year of
blood withdrawal (using the cosinor model). Model 3: model 2 + active
smoking, history of myocardial infarction or stroke, hypertension, hyper-
cholesterolemia, obesity (body mass index> 30 kg/m2), atrial ﬁbrillation,
urinary albumin excretion, highly sensitive C-reactive protein, Cystatin C,
and estimated glomerular ﬁltration rate. Model 4: model 3 + N-terminal
pro-Brain-type Natriuretic peptide and highly sensitive troponin-T.
192 L.M.G. Meems et al.
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increased prevalence of type 2 diabetes, hypertension and a
history of MI, while lower levels of calcitriol were associated
with a higher frequency of type 2 diabetes, but a lower fre-
quency of hypercholesterolemia (Table 1). Higher PTH levels
were associated with higher prevalence of multiple morbid-
ities (hypertension, hypercholesterolemia, type 2 diabetes,
AF, and MI), although we observed an inverse association
with active smokers (Table 1).
Longitudinal associations of calcidiol, calcitriol, and
parathyroid hormone with risk of new onset heart
failure
During a median follow-up time of 12.6 years (IQR: 12.3–
12.9), 281 participants (4%) developed HF, of whom 181
(66%) were classiﬁed with HFrEF and 94 (34%) with HFpEF.
While levels of calcitriol were not different between groups,
subjects that were diagnosed with HF were more likely to
have signiﬁcantly lower calcidiol levels and higher PTH levels.
The levels of calcidiol, calcitriol, and PTH were not signiﬁ-
cantly different in subjects with HFpEF or HFrEF (Table 1).
Univariately, calcidiol levels were per 1 SD increase associ-
ated with new onset HF. However, the association was no
longer signiﬁcant after adjustment for age, sex, and season
of blood withdrawal, and after further adjustment for other
covariates (Figure 3). PTH levels were, per log-transformed
increment, univariately associated with new onset HF [HR
1.79 (95% CI 1.51–2.11)]. This association remained present
after adjustment for age, sex, and season of blood with-
drawal (Figure 3). However, after addition of other
confounders that are associated with risk of new onset HF
this association was no longer signiﬁcant [HR 1.17 (95% CI
0.97–1.41)]. Addition of the biomarkers NT-proBNP and hs-TnT
to this model further attenuated this association (Figure 3).
We performed cause-speciﬁc analyses to analyse if
calcidiol, calcitriol, and PTH could be of importance in differ-
entiating between new onset HFrEF or HFpEF. None of these
markers could differentiate between new onset HFrEF or new
onset HFpEF (Figure 4).
Table 2 Cross-sectional analysis on the association between calcidiol, calcitriol, and PTH with demographics, baseline medical history,
and laboratory values
PTH P-value Calcidiol P-value Calcitriol P-value
Log-transformed coefﬁcient Beta coefﬁcient Beta coefﬁcient
Age (years) 0.30 <0.001 -0.02 0.09 -0.01 0.55
Males (%) -0.05 <0.001 0.01 0.36 0.08 <0.001
Race (%)
Caucasian 1.00 ref 1.00 ref 1.00 ref
Negroid 0.05 <0.001 -0.11 <0.001 -0.01 0.52
Asian 0.05 <0.001 -0.13 <0.001 -0.03 0.02
Other 0.06 <0.001 -0.10 <0.001 -0.02 0.04
BMI (kg/m2) 0.24 <0.001 -0.08 <0.001 -0.02 0.04
SBP (mmHg) 0.25 <0.001 -0.04 0.001 0.02 0.05
DBP (mmHg) 0.21 <0.001 -0.02 0.15 0.02 0.03
Blood withdrawal in winter -0.04 0.72 0.33 <0.001 0.38 <0.001
Smoking or quit <1 year -0.22 <0.001 -0.04 <0.001 -0.09 <0.001
Myocardial infarction (%) 0.06 <0.001 -0.02 0.05 -0.02 0.12
Hypertension (%) 0.23 <0.001 -0.03 0.01 0.01 0.21
Hypercholesterolemia (%) 0.07 <0.001 0.00 0.69 0.04 <0.001
Type 2 diabetes (%) 0.04 0.001 -0.03 0.01 -0.03 0.01
Atrial ﬁbrillation (%) 0.04 0.002 -0.02 0.13 0.00 0.93
Glucose (mmol/L) 0.12 <0.001 -0.01 0.30 0.03 0.004
Total cholesterol (mmol/L) 0.07 <0.001 0.00 0.72 0.03 0.01
HDL cholesterol (mmol/L) -0.06 <0.001 0.09 <0.001 0.11 <0.001
Triglicerides (mmol/L) 0.08 <0.001 -0.04 0.001 -0.02 0.07
Serum creatinin (μmol/L) 0.09 <0.001 0.13 <0.001 -0.09 <0.001
eGFR (mL/min/1.73m2) -0.12 <0.001 -0.17 <0.001 0.02 0.15
Cystatin-C (mg/dL) 0.09 <0.001 0.03 0.03 -0.09 <0.001
hs-CRP (mg/L) 0.06 <0.001 0.01 0.25 0.03 0.01
hs-TnT (ng/L) 0.18 <0.001 -0.02 0.05 -0.05 <0.001
NT-proBNP (ng/L) 0.14 <0.001 0.00 0.69 0.01 0.21
Renin concentration (μIU/mL) -0.08 <0.001 -0.05 <0.001 -0.12 <0.001
UAE (mg/24 h) 0.12 <0.001 -0.03 0.01 -0.02 0.05
Calcidiol (nmol/L) -0.24 <0.001 0.54 <0.001
Calcitriol (pmol/L) 0.01 0.96 0.54 <0.001
PTH (pmol/L) -0.24 <0.001 0.00 0.96
Data are presented per each SD-increment of plasma calcidiol and calcitriol, and per SD log-transformed increase of PTH. DBP, diastolic
blood pressure; eGFR, estimated glomerular ﬁltration rate; HDL, high-density lipoprotein; hs-CRP, highly sensitive C-reactive protein; hs-
TnT, highly sensitive troponin T; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; PTH, parathyroid hormone; SBP, systolic blood
pressure; UAE, urinary albumin excretion.
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Discussion
In this population-based study, neither plasma calcidiol,
calcitriol, nor PTH were independently associated with risk
of new onset HF. Plasma calcidiol and PTH levels were
univariately associated with risk of new onset HF. However,
after adjustment for age, sex, and time of the year of blood
withdrawal calcidiol was no longer associated, whilst plasma
PTH lost its predictive value after addition of other covariates
to our model. In addition, we observed that calcidiol and
calcitriol levels strongly depended on season of blood with-
drawal and that PTH levels were more consistent during the
year. Levels of calcidiol and calcitriol were strongly associated
with each other, and although PTH is a well-known key regu-
lator in vitamin D biology, we did not observe a cross-
sectional association with plasma calcitriol and PTH. The
association between plasma calcitriol and PTH was only mod-
erate in this cohort of healthy subjects.
The observation that PTH is not associated with risk of new
onset HF is in line with results from The Atherosclerosis Risk
in Communities (ARIC) study,21 but contrasts with data from
the Multi-Ethnic Study of Atherosclerosis (MESA), suggesting
that PTH is a predictor for new onset HF.22 These discrepan-
cies might be (indirectly) driven by differences in study
population. The average age of participants in the MESA
(62 years) was markedly higher than in ARICs (range:
56–57 years) and PREVENDs (49 years). In general, kidney
function declines with age and changes in PTH levels are pre-
dominantly present in patients with advanced stages of
chronic kidney disease.23 Independent from kidney function,
increasing age itself is associated with increased plasma PTH
concentrations,24,25 and it has even been suggested to take
this effect into account when assessing calcium disorders in
elderly individuals.26 We therefore hypothesize that, despite
proper adjustment of age as confounding variable in ARIC,
MESA, and our study, differences in (baseline) age have been
a major factor in the reported discrepancies. We hypothesize
that the (indirect) effect of differences in age has driven the
reported discrepancies. Even though not directly within the
scope of our study, we observed a univariate signiﬁcant inter-
action between age, PTH, and risk of new onset HF that was
lost after addition of sex, and time of year of blood withdrawal
(data not shown). We suggest that future research should use
accurately pre-set age categories to reveal if an interaction be-
tween age and PTH is of importance when assessing the asso-
ciation with new onset HF. Based on data from this and ARIC
study, however, it appears that screening for PTH to identify
subjects at risk for new onset HF has limited value.
PTH is part of a complex endocrine system that regulates
calcium and bone metabolism and initiates integration of
many factors, including the vitamin D metabolites calcidiol
and calcitriol. Calcidiol is the storage form of vitamin D in
the human body, and levels of this metabolite are used to de-
termine vitamin D status. However, biological activity of vita-
min D does not only rely on calcidiol, and instead, calcitriol is
considered to be the primary and biologically most active me-
tabolite in vitamin D biology.27 Previous studies have mainly
focused on the role of calcidiol as risk marker in HF, and
the value of measuring circulating calcitriol to predict new
onset HF has not been studied before.
Experimental studies in mice lacking the vitamin D receptor
(VDR/mice) demonstrated that deﬁciency of the VDR results
in cardiac hypertrophy and hypertension. So mechanistically,
vitamin D is thought to directly inﬂuence HF pathology by reg-
ulating myocyte contractility, cardiac remodelling (regulation of
inﬂammation and cytokines), secretion of natriuretic hor-
mones, and activity of the renin–angiotensin–aldosteron sys-
tem.28 However, disappointing outcomes from experimental
and epidemiological studies in humans have tempered the en-
thusiasm that this can be translated easily.29–31 In line with this,
we now show that both plasma calcidiol and calcitriol have no
predictive value in identifying subjects at risk for new onset HF
in the general population. Therefore, we consider the role for
vitamin D as direct modiﬁer in HF pathology a limited one.
Although vitamin D may thus not have added value in
predicting new onset HF in the general population, it may still
be useful in reducing morbidity and mortality prevalence in
patients with HF. The number of morbidities increases with
age,32,33 and it is known that patients with HF often have
Figure 4 Risk ratio for new onset HFrEF or HFpEF (HR (95% CI)] per 1 SD
increment in plasma calcidiol, calcitriol, or per log-transformed increase
in PTH levels, and their incremental power between HFrEF and HFpEF
(Pcr-value). In our full model, we adjusted for age, sex, active smoking,
history of myocardial infarction or stroke, hypertension, hypercholester-
olemia, obesity (body mass index> 30 kg/m
2
), atrial ﬁbrillation, urinary
albumin excretion, highly sensitive C-reactive protein, N-terminal pro-
brain-type natriuretic peptide, highly sensitive troponin T, Cystatin C, es-
timated glomerular ﬁltration rate, and the cosinor model for time of the
year of blood withdrawal.
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multiple co-morbidities.34 Unfortunately, patients with co-
morbid conditions are more likely to have an advanced stage
of HF,34,35 with a concomitant increased risk for both HF hos-
pitalization and overall mortality.35 It is, therefore, of rele-
vance to establish screening tools that help identifying those
patients at risk for increased co-morbidity prevalence.36 Inter-
estingly, low levels of vitamin D are associated with abnormal-
ities in laboratory values (e.g. increased serum LDL
cholesterol, triglycerides, and decreased serum HDL choles-
terol) as well as increased prevalence of frequently reported
co-morbidities in patients with HF, such as hypertension and
diabetes mellitus.37 Moreover, vitamin D deﬁciency is also as-
sociated with increased morbidity prevalence in a general
population.33 We, therefore, hypothesize that vitamin D re-
ﬂects an individual’s global health status. Possibly, low levels
of vitamin D may be used to identify subjects with overall
poor general health who are at risk for increased morbidity
prevalence. Further studies are needed to address if screening
for vitamin D deﬁciency could be of added value in the reduc-
tion of morbidity and mortality burden in patients with HF.
Strengths and limitations
PREVEND is a large, well-phenotyped, community-based co-
hort study with a long follow-up. Within this study, extensive
information is available on several covariates of study sub-
jects, including sensitive biomarkers that minimizes residual
confounding. The validation of incident heart diagnosis has
been thorough, and we used a sensitive method, liquid
chromatography–tandem mass spectrometry to measure
both calcidiol and calcitriol.
This study had several limitations. First, we used a retro-
spective approach to identify new onset HF. Although all cases
were evaluated by seven independent experts in the ﬁeld of
HF, this could have caused detection bias, especially resulting
in the underdetection of subjects with HFpEF. Second, we de-
ﬁned prevalent HF at baseline by self-reported HF, and there-
fore cannot exclude that subjects may have had an episode of
HF or suffered from prevalent HF without reporting this.
Third, PREVEND study subjects were predominantly white.
External validity of our ﬁndings may be limited to white adults,
and results may therefore not be readily extrapolated to other
ethnicities. Finally, because of the design of the study, there
was an enrichment of subjects with mildly elevated urinary al-
bumin concentrations. However, we corrected for this in all
analyses. Although we did not ﬁnd an interaction between
vitamin D and urinary albumin concentrations, we cannot fully
ensure that this study design has not affected our results.
Conclusion
In this well-characterized, community-based cohort, we have
shown that a single measurement of plasma calcidiol,
calcitriol, or PTH does not predict new onset HF. Furthermore,
we found that plasma calcidiol, calcitriol, and PTH were un-
able to distinguish between new onset of HFrEF and HFpEF.
Based on these data, screening for these markers to identify
subjects at risk for new onset HF cannot be advocated.
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